Incruse Ellipta Aerosol, Powder
Product Images NDC 0173-0873

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Incruse Ellipta (NDC 0173-0873). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Umeclidinium Chemical Structure (Incruse Ellipta Spl Graphic 01)

FDA Label Image

Figure 1. Impact Of Intrinsic And Extrinsic Factors On The Systemic Exposure Of Umeclidinium (Incruse Ellipta Spl Graphic 02)

This text provides information on the population demographics (age and gender) and their potential impact on drug exposure (AUC and Cmax) for various medical conditions such as severe renal impairment and moderate hepatic impairment. The text also mentions the effect of Conax, a €YP2D6 inhibitor, and Veraparmil, a P-gp transport inhibitor, on AUC. The fold change and 90% CI are also indicated in the text, which suggests that no dose adjustment is required for the given conditions.*

FDA Label Image

Figure 2. Adjusted Mean Change From Baseline In Postdose Serial Fev1 (ml) On Days 1 And 7, Day 1 (Incruse Ellipta Spl Graphic 03)

This text appears to be a table or graph displaying adjusted mean changes in FEV (forced expiratory volume) measured in mL over time for two different treatments, placebo and Umedidinim (at different doses). There are five data points for each treatment, but the specific time frame or duration of the study is not provided. The text also includes dosages for Umedidinim at 156 mc, 3125 mcg, 125 mcg, and 625 mcg, with some reference to dosing schedule. However, without additional context or explanation, the significance or interpretation of these numbers is not clear.*

FDA Label Image

Figure 2. Adjusted Mean Change From Baseline In Postdose Serial Fev1 (ml) On Days 1 And 7, Day 7 (Incruse Ellipta Spl Graphic 04)

FDA Label Image

Figure 3. Least Squares (ls) Mean Change From Baseline In Fev1 (ml) Over Time (0-24 H) On Days 1 And 168 (trial 1 Subset Population), Day 1 (Incruse Ellipta Spl Graphic 05)

FDA Label Image

Figure 3. Least Squares (ls) Mean Change From Baseline In Fev1 (ml) Over Time (0-24 H) On Days 1 And 168 (trial 1 Subset Population), Day 168 (Incruse Ellipta Spl Graphic 06)

The text appears to be a statistical output and indicates the change from baseline in milliliters for a placebo group and a group receiving Umeclidinium 625 mcg ek at 2 hours. The rest of the output is not available.*

FDA Label Image

Parts Figure (Incruse Ellipta Spl Graphic 07)

This is a generic and brief product description. The text indicates that there is a tray lid and a carton, but no specific details are provided. It could represent any product that includes these components.*

FDA Label Image

Ifu Figure A.jpg (Incruse Ellipta Spl Graphic 08)

FDA Label Image

Ifu Figure B (Incruse Ellipta Spl Graphic 09)

FDA Label Image

Ifu Figure C.jpg (Incruse Ellipta Spl Graphic 10)

FDA Label Image

Ifu Figure D.jpg (Incruse Ellipta Spl Graphic 11)

This text is not useful and cannot be evaluated because it consists of random characters and symbols.*

FDA Label Image

Ifu Figure E (Incruse Ellipta Spl Graphic 12)

FDA Label Image

Ifu Figure F (Incruse Ellipta Spl Graphic 13)

FDA Label Image

Ifu Figure G.jpg (Incruse Ellipta Spl Graphic 14)

FDA Label Image

Ifu Figure I.jpg (Incruse Ellipta Spl Graphic 15)

FDA Label Image

Ifu Figure I (Incruse Ellipta Spl Graphic 16)

FDA Label Image

Ifu Figure J.jpg (Incruse Ellipta Spl Graphic 17)

FDA Label Image

Ifu Figure K.jpg (Incruse Ellipta Spl Graphic 18)

FDA Label Image

Incruse Ellipta 30 Count Carton (Incruse Ellipta Spl Graphic 19)

INCRUSE is a prescription medication that comes in an inhalation powder form for oral inhalation only. Each blister contains 62.5 mcg of umedlidinium, magnesium stearate, and lactose monohydrate. The medication is delivered with an ELLIPTA inhaler that contains 1 Fol Strip of 30 blisters. NDC code is 0173-0873-10.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.